Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2

Freestyle Libre 2 - Continuous Glucose Monitoring System

PDF) Landscape of Continuous Glucose Monitoring (CGM) and Integrated CGM: Accuracy Considerations

Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards

2 Million Patients And Beyond: Abbott's FreeStyle Libre 2 Cleared In The U.S. For Adults And Children With Diabetes

FreeStyle Libre 2 System (CGM)

What to know about diabetes today

FreeStyle Libre Continuous Glucose Monitoring

Emerging Diabetes Technologies: Continuous Glucose Monitors/Artificial Pancreases

Cost and Insurance Coverage